May 21 2012
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company
committed to transforming medicine that transforms lives, presented data
today from a Phase 1 study that found that the investigational compound,
PA32540, provides faster protection compared with delayed-release,
enteric-coated omeprazole (40 mg), as measured by mean time to gastric
pH. These data were presented for the first time at Digestive Disease
Week (DDW) 2012 in San Diego, California at the San Diego Convention
Center on May 19, 2012, at 9:15 a.m. (PT).
"In this study, the mean time to a gastric pH of greater than 4.0 was
faster with PA32540 than with 40 mg of delayed-release, enteric-coated
omeprazole," said Philip B. Miner, Jr., M.D., President and Medical
Director of the Oklahoma Foundation for Digestive Research and co-author
of the study. "In addition, the 24-hour pH control achieved with the
immediate release form of omeprazole in PA32540 should be sufficient for
control of gastric acidity in patients taking chronic aspirin therapy
for secondary cardiovascular prevention."
Source: POZEN Inc.
AI in medicine: Revolutionary tools, uncertain results